An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis
Applied Health Economics and Health Policy · 2026-11 · 24 (6) · 1093-1108
DOI: 10.1007/s40258-026-01075-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 30.09.2026. Verfasst von Teebah Abu-Zahra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherland…. Hauptthemen laut MEDLINE: Hypertension, Precision Medicine, Antihypertensive Agents. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Health and Digital Executive Agency.
Abstract (Originalsprache)
BACKGROUND: Treatment-resistant hypertension (TRH), defined as uncontrolled blood pressure despite the use of three or more antihypertensive drugs or requiring four or more drugs for control, affects 10.3% of patients with hypertension and increases cardiovascular risk. Biomarker-guided precision treatments have the potential to address unmet needs in TRH. This health economic modelling study assessed the headroom (that is the maximum potential value of a hypothetical biomarker-guided treatment strategy with zero treatment costs and 100% effectiveness) in the TRH population in general, then in a specific subgroup with elevated levels of NADPH oxidase 5 (NOX5-positive). METHODS: A decision tree and a state transition model were developed to estimate headroom in patients with TRH and in the NOX5-positive subgroup (assumed to comprise 25% of the population). The model adopted a Dutch healthcare perspective over a lifetime horizon, estimating costs and quality-adjusted life years (QALYs), with a net monetary benefit threshold of €20,000 per QALY. Uncertainty was explored through sensitivity, scenario and threshold analyses. RESULTS: The room for improvement in TRH patients includes 2.94 additional life years, 3.45 QALYs, and €23,292 cost savings per patient. Successfully diagnosing and treating NOX5-positive patients could yield a gain of 0.53 life years and 0.63 QALYs, with cost savings of €4835 per patient. The biomarker-guided treatment remained cost effective even at annual costs of €5045 per patient or if only two of 1000 patients were NOX5-positive and successfully treated. CONCLUSION: Patients with TRH have room for improvement in life expectancy, quality of life, and cardiovascular outcomes with a biomarker-guided treatment strategy. These findings support further research and development of targeted treatments to address this unmet medical need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands. Teebah.abu-zahra@mumc.nl.
- Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. Teebah.abu-zahra@mumc.nl.
- Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
- Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
- Departments of Medical Imaging and IQ health, Radboudumc, Nijmegen, The Netherlands.
- Department of Neurology and Center for Translational Neuro- and Behavioural Sciences (C-TNBS), Clinic for Neurology, University Hospital Essen, Essen, Germany.
Förderung
- European Health and Digital Executive Agency
Zitieren
APA
Abu-Zahra, T., Grimm, S., Scholte, M., Casas, A. I., Saliba-Gustafsson, P., Parini, P., & Joore, M. (2026). An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis. Applied Health Economics and Health Policy, 24(6), 1093-1108. https://doi.org/10.1007/s40258-026-01075-x
Vancouver
Abu-Zahra T, Grimm S, Scholte M, Casas AI, Saliba-Gustafsson P, Parini P, et al. An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis. Applied Health Economics and Health Policy. 2026;24(6):1093-1108. doi:10.1007/s40258-026-01075-x
BibTeX
@article{AbuZahra2026,
author = {Abu-Zahra, Teebah and Grimm, Sabine and Scholte, Mirre and Casas, Ana I and Saliba-Gustafsson, Peter and Parini, Paolo and Joore, Manuela},
title = {An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis},
journal = {Applied Health Economics and Health Policy},
year = {2026},
volume = {24},
number = {6},
pages = {1093--1108},
doi = {10.1007/s40258-026-01075-x}
}
EUVIMED